Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN: BMN 333 vs Vosoritide in Children With Achondroplasia
NCT07441876Phase 3Recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- Peptides
- Countries
- 9
01
Overview
A Phase 3 trial of BMN 333 in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
BMN 333
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT07441876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441876.